Cormorant Asset Management
Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles.
Business Model:
Revenue: $27.4M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Cormorant Asset Management Information
Geographic Data
Address:
City: Chagrin Falls
State: OH
Zip: 44022
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$253M
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace. Cormorant Asset Management was founded in 2013 and is based in Boston, Massachusetts, United States.
Contact Phone:
+14402473200
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 3/2015 | Minerva Neuroscience | Post-IPO Equity | 0 |
| 10/2016 | Bigfoot Biomedical | Series A | 0 |
| 2/2022 | Greenlight Biosciences | Post-IPO Equity | 0 |
| 1/2021 | Visen Pharmaceuticals | Series B | 0 |
| 9/2020 | Korro Bio | Series A | 0 |
| 9/2021 | BioAtla | Post-IPO Equity | 0 |
| 4/2022 | MoonLake Immunotherapeutics | Post-IPO Equity | 115M |
| 5/2021 | BiVACOR | Series B | 19M |
| 4/2023 | BioVentrix | Series A | 0 |
| 4/2015 | Jounce Therapeutics | Series B | 0 |
| 1/2021 | FogPharma | Series C | 107M |
| 9/2015 | Aclaris Therapeutics | Series C | 40M |
| 9/2021 | 858 Therapeutics | Series A | 0 |
| 5/2017 | Axonics Modulation Technologies | Series C | 0 |
| 3/2021 | EpimAb Biotherapeutics | Series C | 0 |
| 6/2015 | Ardelyx | Post-IPO Equity | 77.8M |
| 3/2021 | Pyxis Oncology | Series B | 152M |
| 9/2017 | Replimune Group | Series B | 55M |
| 4/2020 | Erasca | Series B | 0 |
| 1/2018 | Scholar Rock | Series C | 47M |
| 9/2018 | Atreca | Series C | 125M |
| 8/2017 | Atreca | Series B | 35M |
| 6/2021 | Myra Vision | Series A | 17M |
| 11/2020 | Pharvaris | Series C | 80M |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 3/2021 | Chemomab | Post-IPO Equity | 45.5M |
| 4/2021 | Ventus Therapeutics | Series B | 100M |
| 1/2021 | Verve Therapeutics | Series B | 94M |
| 8/2021 | Vigil Neuroscience | Series B | 0 |
| 7/2020 | Olema Oncology | Series B | 54M |
| 9/2020 | I-Mab Biopharma | Post-IPO Equity | 0 |
| 2/2016 | Apellis Pharmaceuticals | Series D | 47M |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 12/2020 | Edgewise Therapeutics | Series C | 95M |
| 3/2023 | CARGO Therapeutics | Series A | 0 |
| 5/2017 | Turning Point Therapeutics | Series C | 45M |
| 11/2020 | Elevation Oncology | Series B | 65M |
| 5/2021 | NiKang Therapeutics | Series C | 200M |
| 9/2020 | Novellus | Series C | 57M |
| 10/2022 | Orionis Biosciences | Series C | 55M |
| 8/2020 | Freenome | Series C | 270M |
| 2/2020 | ALX Oncology | Series C | 105M |
| 6/2021 | Umoja Biopharma | Series B | 0 |
| 7/2021 | Tioga Medical | Series B | 0 |
| 3/2018 | Bigfoot Biomedical | Series B | 0 |
| 12/2018 | Akero Therapeutics | Series B | 70M |
| 9/2020 | Rain Therapeutics | Series B | 63M |
| 1/2021 | Biomea Fusion | Series A | 56M |
| 1/2022 | Enliven Therapeutics | Series B | 0 |
| 11/2017 | Tricida | Series D | 0 |
| 12/2015 | X4 Pharmaceuticals | Series A | 37.5M |
| 12/2018 | Atia Vision | Series C | 10M |
| 3/2021 | BlossomHill Therapeutics | Series A | 71M |
| 3/2017 | Dicerna Pharmaceuticals | Post-IPO Debt | 0 |
| 6/2018 | Cibus | Series C | 70M |
| 2/2018 | Avrobio | Series B | 60M |
| 4/2018 | Supira Medical | Series A | 15.5M |
| 6/2015 | Kezar Life Sciences | Series A | 23M |
| 11/2020 | Ambrx | Private Equity Round | 200M |
| 12/2018 | Erasca | Series A | 42M |
| 11/2021 | Chroma Medicine | Series A | 125M |
| 3/2020 | Design Therapeutics | Series A | 45.5M |
| 8/2020 | Tango Therapeutics | Venture Round | 50M |
| 9/2020 | Adona Medical | Series A | 0 |
| 4/2022 | Adona Medical | Series B | 0 |
| 10/2021 | ShouTi | Series B | 0 |
| 6/2019 | Viela Bio | Series B | 0 |
| 2/2021 | Ensoma | Series A | 0 |
| 1/2016 | Twist Bioscience | Series D | 61M |
| 8/2020 | Aerovate Therapeutics | Series A | 72.6M |
| 11/2017 | X4 Pharmaceuticals | Series B | 27M |
| 2/2018 | Kiniksa Pharmaceuticals | Series C | 200M |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
| 10/2017 | InflaRx | Series D | 55M |
| 5/2020 | Atea | Series D | 215M |
| 4/2021 | GH Research | Series B | 125M |
| 9/2020 | Galecto | Series D | 0 |
| 7/2015 | AnaptysBio | Series D | 40M |
| 10/2020 | Longboard Pharmaceuticals | Series A | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 2/2019 | NuVera Medical | Series B | 15M |
| 3/2020 | Element Science | Series C | 145.6M |
| 9/2018 | PhaseBio Pharmaceuticals | Series D | 0 |
| 9/2021 | Garuda Therapeutics | Series A | 72M |
| 2/2019 | Neurogene | Series A | 68.5M |
| 6/2020 | Greenlight Biosciences | Series D | 102M |
| 8/2022 | JenaValve Technology | Series C | 0 |
| 1/2023 | Ensoma | Series B | 0 |
| 6/2018 | Iconic Therapeutics | Venture Round | 0 |
| 1/2016 | Scholar Rock | Series B | 36M |
| 1/2016 | Iconic Therapeutics | Series C | 40M |
| 8/2016 | Iconic Therapeutics | Series C | 10M |
| 5/2023 | OnKure Therapeutics | Series C | 0 |
| 8/2021 | Tango Therapeutics | Post-IPO Equity | 0 |
| 4/2021 | Icosavax | Series B | 0 |
| 3/2017 | Solid Biosciences | Series C | 0 |
| 5/2016 | G1 Therapeutics | Series C | 0 |
| 9/2020 | Monte Rosa Therapeutics | Series B | 0 |
| 1/2022 | Korro Bio | Series B | 0 |
| 7/2020 | Praxis Precision Medicines | Series C | 0 |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
| 2/2021 | Artiva Biotherapeutics | Series B | 120M |
| 12/2020 | RayzeBio | Series B | 105M |
| 3/2021 | Monte Rosa Therapeutics | Series C | 0 |
| 3/2020 | Akouos | Series B | 105M |
| 6/2021 | Stablix | Series A | 63M |
| 8/2022 | Greenlight Biosciences | Post-IPO Equity | 0 |
| 8/2017 | Apellis Pharmaceuticals | Series E | 0 |
| 4/2022 | Tessera Therapeutics | Series C | 0 |
| 3/2017 | 908 Devices | Series D | 20M |
| 8/2015 | Wave Life Sciences | Series B | 66M |
| 9/2020 | Fore Biotherapeutics | Series C | 57M |
| 6/2017 | Zai Lab | Series C | 30M |
| 3/2021 | Ventyx Biosciences | Series A | 0 |
| 9/2020 | BioShin | Series A | 60M |
| 5/2021 | Jenscare Biotech | Venture Round | - |
| 7/2020 | BioAtla | Series D | 0 |
| 4/2020 | Tango Therapeutics | Series B | 60M |
| 11/2021 | Shoreline Biosciences | Series B | 0 |
| 1/2021 | Design Therapeutics | Series B | 125M |
| 6/2016 | Mersana Therapeutics | Series C | 33M |
| 6/2023 | Myra Vision | Series B | 0 |
| 1/2021 | Beam Therapeutics | Post-IPO Equity | 260M |
| 9/2020 | Eledon Pharmaceuticals | Post-IPO Equity | 108M |
| 4/2015 | MyoKardia | Series B | 0 |
| 2/2015 | Advaxis | Post-IPO Equity | 0 |
| 1/2022 | ONK Therapeutics | Series A | 21.5M |
| 2/2021 | Centessa Pharmaceuticals | Series A | 250M |
| 12/2015 | Gelesis | Private Equity Round | 0 |
| 7/2020 | VelosBio | Series B | 137M |
| 3/2021 | OnKure | Series B | 56.6M |
| 8/2018 | Orchard Therapeutics | Series C | 0 |
| 5/2021 | Numab | Series C | 110.6M |
| 1/2020 | Aligos Therapeutics | Series B | 125M |
| 9/2017 | Autolus | Series C | 80M |
| 1/2022 | Akura Medical | Series A | 25M |
| 8/2015 | Ovid Therapeutics | Series B | 75M |
| 12/2021 | connectRN | Venture Round | 0 |
| 7/2021 | Prime Medicine | Series B | 200M |
| 10/2020 | Talaris Therapeutics | Series B | 0 |
| 4/2018 | Corvidia | Series B | 60M |
| 2/2022 | Star Therapeutics | Venture Round | 0 |
| 3/2016 | ImmuneXcite | Series A | 8.6M |
| 8/2014 | MyoKardia | Venture Round | 0 |
| 7/2017 | Kezar Life Sciences | Series B | 0 |
| 3/2020 | Pliant Therapeutics | Series C | 0 |
| 12/2017 | Bigfoot Biomedical | Series B | 0 |
| 12/2015 | Axonics Modulation Technologies | Series B | 0 |
| 5/2021 | Elpiscience Biopharmaceuticals | Series C | 0 |
| 2/2023 | Tioga Cardiovascular | Series C | 0 |
| 11/2022 | BioAtla | Post-IPO Equity | 0 |
| 4/2018 | Constellation Pharmaceuticals | Series F | 0 |
| 7/2021 | Strata Oncology | Series C | 0 |
| 6/2015 | CytomX Therapeutics | Series D | 70M |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 6/2021 | RayzeBio | Series C | 108M |
| 3/2021 | AgomAb Therapeutics | Series B | 0 |
| 3/2021 | Tyra Biosciences | Series B | 106M |
| 4/2020 | MOMA Therapeutics | Series A | 86M |
| 10/2018 | Turning Point Therapeutics | Equity | 80M |
| 4/2018 | Innovent Biologics | Series E | 150M |
| 4/2017 | NuVera Medical | Series A | 11M |
| 10/2021 | Structure Therapeutics | Series B | 0 |
| 3/2021 | DTx Pharma | Series B | 100M |
| 11/2022 | FogPharma | Series D | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 11/2019 | Avidity Biosciences | Series C | 0 |
| 1/2020 | Bigfoot Biomedical | Series C | 0 |
| 2/2022 | Arkuda Therapeutics | Series B | 0 |
| 7/2020 | New Horizon Health | Series E | 30M |
| 6/2021 | Myra Vision | Series A | 17M |
| 5/2015 | REGENXBIO | Series D | 0 |
| 8/2022 | Atia Vision | Series E | 0 |
| 1/2016 | C4 Therapeutics | Series A | 73M |
| 9/2020 | Flame Biosciences | Venture Round | 100M |
| 8/2018 | Renovia | Series B | 32.3M |
| 9/2015 | Proteostasis Therapeutics | Series B | 37M |
| 3/2020 | Supira Medical | Series B | 0 |
| 7/2017 | Axonics Modulation Technologies | Series C | 20.5M |
| 3/2021 | Neurelis | Series D | 0 |
| 10/2020 | Olema Oncology | Series C | 85M |
| 5/2021 | Interius BioTherapeutics | Series A | 0 |
| 2/2022 | Electra Therapeutics | Series B | 0 |
| 9/2021 | Expansion Therapeutics | Series B | 80M |
| 4/2018 | Eidos Therapeutics | Series B | 0 |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 3/2019 | Beam Therapeutics | Series B | 135M |
| 7/2016 | Ardelyx | Post-IPO Equity | 0 |
| 3/2016 | Quanterix | Series D | 46M |
| 12/2019 | FORMA Therapeutics | Series D | 100M |
| 12/2015 | Clearside Biomedical | Series C | 20M |
| 2/2022 | Supira Medical | Series C | 0 |
| 5/2019 | Atia Vision | Series D | 0 |
| 6/2023 | Myra Vision | Series B | 0 |
| 5/2023 | OnKure Therapeutics | Series C | 0 |
| 4/2023 | BioVentrix | Series A | 0 |
| 3/2023 | CARGO Therapeutics | Series A | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 2/2023 | Tioga Cardiovascular | Series C | 0 |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 1/2023 | Ensoma | Series B | 0 |
| 11/2022 | FogPharma | Series D | 0 |
| 11/2022 | BioAtla | Post-IPO Equity | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
